On 13 September 2024, Eli Lilly announced that its Ebglyss® (lebrikizumab-lbkz) received FDA approval for adults and children 12 years and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
Eli Lilly’s partner, Spanish pharmaceutical company, Almirall S.A., has licensed the rights to develop and commercialise Ebglyss® in Europe for the treatment of dermatology indications, including eczema. Eli Lilly retains exclusive rights to develop and develop and commercialise Ebglyss® in the rest of the world .
In November 2023, Almirall received marketing authorisation from the European Commission for Ebglyss® for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Ebglyss® was also approved in Japan in January 2024.